MCL1 and acute myeloid leukemia: FLT3 and ITD mutations in AML seem to confer resistance to venetoclax treatment by enhancing the expression of anti-apoptotic proteins (BCL-xL and MCL1), explaining the relatively weak response to venetoclax-based regimens noted in patients harboring these alterations [26,40,41].